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SignalingLiver X receptors (LXRs) are ligand-dependent transcription factors that are activated by metabolites of
cholesterol, oxysterols, and a number of synthetic agonists. LXRs play potent anti-atherogenic roles in part by
stimulating the efﬂux of cholesterol from macrophage foam cells. The LXR-induced expression of ATP-binding
cassette transporter (ABC)-A1 and Apolipoprotein E (ApoE) in macrophages is essential for the stimulation of
cholesterol efﬂux and the prevention of atherosclerotic development. Unfortunately, the signaling pathways
underlying such regulation are poorly understood and were therefore investigated in human macrophages. The
expression of ApoE and ABCA1 induced by synthetic or natural LXR ligands [TO901317, GW3965, and 22-(R)-
hydroxycholesterol (22-(R)-HC), respectively] was attenuated by inhibitors of c-Jun N-terminal kinase (JNK)
(curcumin and SP600125) and phosphoinositide 3-kinase (PI3K) (LY294002). Similar resultswere obtainedwith
ABCG1 and LXR-α, two other LXR target genes. LXR agonists activated several components of the JNK pathway
(SEK1, JNK and c-Jun) along with AKT, a downstream target for PI3K. In addition, dominant negative mutants of
JNK and PI3K pathways inhibited the LXR-agonists-induced activity of the ABCA1 and LXR-α gene promoters in
transfected cells. LXR agonists also induced the binding of activator protein-1 (AP-1), a key transcription factor
family regulated by JNK, to recognition sequences present in the regulatory regions of the ApoE andABCA1genes.
These studies reveal a novel role for JNK and PI3K/AKT signaling in the LXR-regulated expression inmacrophages
of several key genes implicated in atherosclerosis.+44 29 20874116.
-NC-ND license. © 2010 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Liver X receptors (LXRs) belong to the nuclear receptor family of
transcriptional regulators that are emerging as key modulators of lipid
metabolism and inﬂammation [1,2]. They play important roles in
diseases associated with perturbations in these processes, such as
atherosclerosis, obesity and diabetes [1,2]. There are two LXRs, LXRα
and LXRβ,with the latter expressedubiquitously and the formerpresent
at high levels in a restricted set of tissues/cell types, including
macrophages [1,2]. Both LXRs are activated by oxidized derivatives of
cholesterol [e.g., 22R-hydroxycholesterol (22-(R)-HC), 27-hydroxycho-
lesterol and 24(S), 25-epoxycholesterol] and therefore act as intracel-
lular sensors of cholesterol [1,2]. Ligand-activated LXRs form obligate
heterodimers with the retinoid X receptor (RXR) and regulate the
transcription of target genes containing LXR response element(s) [1,2].
Such target genes include those implicated in the efﬂux of cellular
cholesterol [e.g., Apolipoprotein E (ApoE), ATP-binding cassette
transporter (ABC)-A1] and fatty acid metabolism [e.g., sterol response
element binding protein 1c] [1,2]. The expression of the LXRα gene isalso subject to autoregulation [3]. In addition, LXR activators inhibit
inﬂammatory gene expression by antagonizing the actions of key
transcription factors, such as nuclear factor κB, largely via a mechanism
that does not require sequence-speciﬁc DNA binding by the LXRs [1,2].
A number of in vitro and in vivo studies have revealed potent anti-
atherogenic roles for the LXRs [1,2]. For example, cholesterol and bile
metabolism are impaired in mice lacking LXRα [1,2], and the removal
of LXR from the hematopoietic compartment by bone marrow
transplantation results in a marked increase in atherosclerotic lesion
formation in murine models of this disease [4]. The administration of
LXR agonists also leads to a reduction in lesion development in such
model systems [5]. Additionally, the overexpression of the LXRs or
their ligand-dependent activation stimulates macrophage cholesterol
efﬂux through the induced expression of several key genes implicated
in the process, including ApoE and ABCA1 [1,2].
The precise mechanisms by which activated LXRs regulate the
transcription of target genes are not fully understood. A putative
model for the co-activator/co-repressor recruitment has been derived
on the basis of some initial studies on LXR-mediated gene trans-
cription and extensive research on other nuclear receptors [1,2,6].
Intracellular signal transduction pathways are also known to regulate
the action of nuclear receptors by the covalent modiﬁcation of the
receptors themselves or other factors required for activation (e.g., co-
activators) [7]. For example, the activity of peroxisome proliferator-
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protein kinases [7]. Unfortunately, very little is currently understood
regarding such regulation of the LXRs. We have investigated this
aspect using ApoE and ABCA1 as model genes. Both these genes are
known to have potent anti-atherogenic actions [8,9]. We show for the
ﬁrst time a novel role for JNK and PI3K signaling pathways in the
response.
2. Materials and methods
2.1. Materials
The human THP-1, U937 and Hep3B cell lines were from the
European Collection of Animal Cell Cultures. The antisera were
obtained from Biogenesis (ApoE), Abcam (ABCA1), Sigma (β-actin),
Santa-Cruz Biotechnology [c-Jun (H-89), phospho-c-Jun (Ser63; KM-1)]
and Cell Signaling Technology [AKT, phospho-AKT (Ser473), SEK1,
phospho-SEK1 (Ser257/Thr261), JNK, phospho-JNK (Thr183/Tyr185)].
The non-radioactive AKT and JNK activity kits were from Cell Signaling
Technology, the inhibitors were from Merck, and the ligands were
from Sigma [22-(R)-HC, 22-(S)-HC, 9cRA], Merck (TO901317)
and GlaxoSmithKline (GW3965). The plasmids used were: ABCA1
promoter-luciferase (−928 to +101) from Philippe Costet (INSERM,
France); LXR-α promoter (−3027 to +463) from Steven Kliewer
(University of Texas Southwestern Medical Centre); and dominant
negative LXR-α (Thomas Kocarek, Wayne State University), AKT and
p110 (Brian Hemmings, FriedrichMiescher-Institut, Basel), JNK (Eisuke
Nishida, Kyoto University), c-Jun (Powel Brown, Bayor College of
Medicine, Texas) and SEK1 (Jim Woodgett, Ontario Cancer Institute).
2.2. Cell culture
Human monocyte-derived macrophages (HMDM) were isolated
from buffy coats as previously described [10–12]. The cells were
maintained in RPMI-1640 (HMDM, THP-1, U937) or DMEM
(Hep3B) with Stabilix supplemented with 10% (v/v) heat-inactivated
FCS (HI-FCS) (56 °C, 30 min) in thepresenceof Penicillin (100 U/ml) and
Streptomycin (100 μg/ml). Differentiation of THP-1 monocytes into
macrophages was carried out by incubation for 24 h with 0.16 μM
phorbol 12-myristate 13-acetate. For experiments involving the use of
LXR ligands, macrophages were incubated in medium containing
dilapidated HI-FCS, prepared as described by Cham and Knowles [13].
For experiments with inhibitors, these were added 1 h before the
addition of the ligands (pre-treatment).
2.3. Real-time quantitative PCR (RT-qPCR)
The total cellular RNA was prepared using the RNeasy™ total RNA
isolation kit or the RNeasy™ Micro kit (Qiagen) and reverse
transcribed into cDNA using M-MLV reverse transcriptase (Promega)
and random hexamer primers. For Taqman RT-qPCR, the reactions
were carried out in a ﬁnal volume of 29 μl containing 25 ng of cDNA,
2× Taqman Master mix (Applied Biosystems), 300 nM of both the 5′
and 3′ primers, and 300 ng of probe (see Supplementary Table I for
sequences). The mixture was overlaid with 12 μl of mineral oil, and
the reactions were cycled on an ABI PRISM 7700 Sequence detector
(Applied Biosystems) using the following program: 50 °C for 2 min
and 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s for
denaturation and at 60 °C for annealing and extension. Each set of
reactions also contained a standard curve, where a range of
concentration of human liver cDNA was employed (0.05 pg/μl to
30 ng/μl). Reactions were monitored in a real-time mode using the
Sequenase Detection Systems version 1.7 software and normalized to
β2-microtubulin. RT-qPCR for ApoE in HMDM was carried out using
the SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma) and primers
against ApoE and 28S rRNA (see Supplementary Table I for thesequences of primers). PCR was performed in optical 96-well plates
using the DNA Engine Opticon 2® real-time PCR detection system (MJ
Research), and transcript levels were determined using the compar-
ative Ct method and normalized to 28S rRNA [10–12]. All PCRs were
performed in duplicate and cDNAs, cloned into pGEM-T® vector, were
used as standards for quantitation and to verify speciﬁcity by DNA
sequencing.
2.4. Western blot analysis and AKT/JNK activity assays
The Western blot analysis of whole cell extracts was carried out as
previously described [14–16], except that samples for ABCA1 were not
boiled for 5 min before loading on the gels as this caused degradation of
this highmolecular weight protein. The AKT and JNK activity assays were
performed as described by themanufacturer (Cell Signaling Technology).
2.5. Transfection of cells and Electrophoretic mobility shift assays (EMSA)
Transfection of U937 and Hep3B cells was carried out essentially as
described previously [14–16]. The radiolabeling of oligonucleotides,
preparation of whole cell and nuclear extracts and EMSA were
carried out as before [14–16]. The sequences of the oligonucleotides
were: 5′-CGCTTGATGAGTCAG-3′ and 5′-TTCCGGCTGACTCAT-3′ (AP-1
consensus probe); 5′-CGCTTGATGAGTCAGCCGGAA-3′ and 5′-
TTCCGGCTGACTCATCAAGCG-3′ (AP-1 consensus competition); 5′-
GGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCAA-3 ′ and 5 ′-
GCTACTTGGGAGGCTGAGGCAGGAGAATCGCTTGA-3′ (AP-1 site from
ApoE promoter); 5′-GCTGAGTGACTGAACTACATAAA-3′ and 5′-
GGTTTATGTAGTTCAGTCACTCAG-3′ (AP-1site from ABCA1 promoter);
5′-CAGTGTTTCCAGAC-3′ and 5′-TTGGTCTGGAAACA-3′ (C/EBP); and
5′-AGTTGAGGGGACTTTCCCAGGC-3′ and 5′-GCCTGGGAAAGTCCCCT-
CAACT-3′ (NF-κB).
2.6. Statistical analyses of data
The signals from Western blots were subjected to densitometric
analysis using the GeneTools software (GRI). Statistical comparisons
between all data were carried out using Student's t test with pb0.05
considered as statistically signiﬁcant.
3. Results
3.1. The induction of gene expression by LXR agonists is attenuated by
inhibitors of JNK and PI3K pathways
The human THP-1 cell line is an extensively used model for the
study of macrophage gene expression in relation to nuclear receptors
and atherosclerosis with demonstrated conservation of numerous
responses in vivo [3,10–12,14,17]. Our initial studies used the
LXR ligand 22-(R)-HC and ApoE as an LXR-inducible model gene.
22-(R)-HC, but not the 22-(S)-HC enantiomer, which binds to the
LXRs but does not activate it, induced the expression of the ApoE
mRNAandproteinbut not that for the control genes (e.g., GAPDH,β-actin,
and PPAR-γ) in THP-1 macrophages (data not shown). RT-qPCR showed
that such 22-(R)-HC-mediated induction of ApoE mRNA expression was
attenuated by inhibitors of JNK (curcumin and SP600125) or PI3K
(LY294002) but not the other two mitogen-activated protein kinase
pathways, extracellular signal-regulated kinase and p38 kinase (PD98059
and SB202190, respectively) (Fig. 1A). Further experiments showed that
curcumin and SP600125 also inhibited the22-(R)-HC-induced expression
of ABCA1, ABCG1 and LXR-α (Fig. 1B). These studies therefore suggested
an important role for the JNK and PI3K pathways in LXR signaling and
were therefore investigated further using ApoE and ABCA1 as model
genes. Because of functional relevance, themajority of subsequent studies
focused on protein expression.
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Fig. 1. The 22-(R)-HC-induced gene expression is attenuated by inhibitors of JNK and
PI3K. THP-1 macrophages were pre-treated for 1 h with the DMSO vehicle (−) or
PD98059 (PD; 50 μM), SB202190 (SB; 10 μM), curcumin (Cur; 25 μM), SP600125 (SP;
50 μM) or LY294002 (LY; 100 μM) as indicated and then exposed for 12 h to vehicle or
22-(R)-HC (2 μg/ml). RT-qPCR was then performed using primers against ApoE, ABCA1,
ABCG1, LXR-α or the constitutive control, β2-microtubulin, as shown. For each
inhibitor, the gene:β2-microtubulin ratio in vehicle-treated cells has been assigned as 1
(not shown) with that in the presence of the ligand represented relative to this. The
data (mean±SD) are from three independent experiments (*pb0.05 and **pb0.005).
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used in conjunction with 9-cis-retinoic acid (9cRA) as endogenous
ligands for the action of this nuclear receptor [18]. Indeed, a marked
activation of ABCA1 protein expression was produced when these
ligands were present together (Supplementary Fig. IA). The induced
expression of ABCA1 was only obtained with 22-(R)-HC but not with
22-(S)-HC. 22-(R)-HC and 9cRA were therefore used for the majority
of subsequent studies. In addition, representative experiments were
performed using the synthetic ligands GW3965 and/or TO901317,
both of which induced ApoE and ABCA1 expression (Supplementary
Fig. IB and C; other data not shown). Unless otherwise stated, the
concentration of the ligands that produced the maximal expression of
ABCA1 expression was used for subsequent studies. In the experi-
ments described above, the cells were incubated with the ligands for
24 h, a period corresponding to the maximal activation of protein
expression as judged by time-course experiments using 22-(R)-HC
and 9cRA or TO901317 (data not shown). These experiments also
showed that a marked induction in expression could be observed
within 3 h of the addition of ligands, thereby indicating a rapid kinetics
of the response (data not shown).
Further experiments investigated the effects of the inhibitors on
such ligand-induced expression of ABCA1 and/or ApoE. Initial studies
using a single concentration of these inhibitors showed that the
induction of both ABCA1 and ApoE expression by 22-(R)-HC plus 9cRA
or GW3965 was inhibited in a statistically signiﬁcant manner by
curcumin, SP600125 and LY294002 (Fig. 2). Similar results were
obtained with 22-(R)-HC alone or TO901317 (Supplementary Fig. II).
Such attenuation in gene expression was also observed with several
concentrations of the inhibitors (Supplementary Figs. III and IV).To conﬁrm that the effect of the inhibitors was not peculiar to THP-1
macrophages, representative experiments were carried out on primary
HMDM using ApoE as a model gene. RT-qPCR was used because of
technical problems with Western blot analysis using extracts from
HMDM. The 22-(R)-HC and 9cRA-induced expression of ApoE mRNA
was inhibited in a statistically signiﬁcant manner by the incubation of
the cells with SP600125, curcumin or LY294002 (Fig. 3A).
3.2. The LXR agonists-induced ABCA1 promoter activity was inhibited by
the expression of dominant negative forms of the components of the JNK
and PI3K pathways
Transfection experiments were performed to further evaluate the
role of the JNK and PI3K pathways in the actions of LXR agonists.
Because of difﬁculties with transfecting THP-1 cells at high efﬁciency,
the human monocytic U937 cell line, which can also be differentiated
into macrophages using phorbol 12-myristate 13-acetate, was used.
Numerous studies have employed this cell line for transfection-based
experiments in relation to the regulation of promoter activity in
macrophages, including by nuclear receptors [16,19]. Initial experi-
ments showed that the ABCA1 gene promoter [20] was activated
markedly by 22-(R)-HC plus 9cRA or TO901317 (data not shown). To
evaluate the roles of different signaling pathways, co-transfection
assays were carried out using plasmids specifying for dominant
negative forms of key components of these pathways. The induction
of ABCA1 promoter activity by these ligands in cells transfected with
the control pcDNA3 plasmid was attenuated by the expression of
dominant negative forms of LXR-α, two components of the JNK
pathway (SEK1 and c-Jun) [21] and AKT, a key downstream target for
PI3K actions (Fig. 3B). In relation to PI3K, representative experiments
were also carried out in the human hepatoma Hep3B cell line using
another target, LXR-α itself [4], to investigate whether the ﬁndings
could be extended to other systems. 22-(R)-HC plus 9cRA induced the
LXR-α promoter activity in these cells and this was inhibited by
dominant negative forms of AKT and the p110 PI3K catalytic subunit
(Supplementary Fig. V). In addition, representative experiments
showed that the expression of dominant negative JNK or SEK1
inhibited the induction of endogenous ApoE expression by 22-(R)-HC
alone (Supplementary Fig. VI).
3.3. LXR agonists activate key components of the JNK and PI3K pathways
and this was attenuated by the corresponding inhibitors
The activation of key components of the JNK and PI3K pathways
can be monitored by Western blot analysis using phospho-speciﬁc
antibodies and/or in vitro kinase assays using immunoprecipitated
proteins. Initial time course analysis showed that 22-(R)-HC plus 9cRA
induced the levels of phospho-AKT and several components of the JNK
pathway with rapid kinetics, with the activation of the JNK pathway
being more prolonged than AKT (data not shown). The action of the
inhibitors on such activation was then determined. 22-(R)-HC and
9cRA induced the levels of phospho-JNK, -SEK1 and -c-Jun, without
affecting the total level of the proteins, and such an activation was
inhibited by SP600125 (Fig. 4A). Because curcumin has been shown to
affect several components of the pathway, its action on JNK activity
was analyzed, where the ability of immunoprecipitated kinase to
phosphorylate c-Jun fusion protein is monitored, with Western blot
analysis using the β-actin antibody used to verify equal amounts of
proteins in extracts. 22-(R)-HC and 9cRA induced JNK activity and this
was inhibited by curcumin (Fig. 4B). Representative experiments also
showed that 22-(R)-HC alone induced JNK activity or phospho-c-Jun
levels and this was inhibited by curcumin and SP600125 (data not
shown). Similarly, the ligands increased phospho-AKT levels, but not
that for the total protein, and this was associated with an increase in
enzymatic activity (Fig. 4C–E). Additionally, the ligand-induced levels
Fig. 2. Induction of ABCA1 andApoE protein expression by LXR agonists is attenuated by inhibitors of JNK and PI3K. THP-1macrophageswere pre-treated for 1 hwith theDMSOvehicle (−) or
the inhibitors (25 μM curcumin, 100 μM SP600125 or LY294002) and then incubated for 24 h with the indicated ligands [2 μg/ml 22-(R)-HC plus 10 μM 9cRA (22R/9cRA), 2 μg/ml 22-(S)-HC
(22S) or 1 μMGW3965]. Equal amounts of proteinswere then subjected toWestern blot analysis using antisera against ABCA1, ApoE orβ-actin. A representative image is presented in panels A
and B and panel C shows the outcome of densitometric analysis of the levels of ABCA1 or ApoE normalized toβ-actin (mean±SD) from three independent experiments (for each inhibitor, the
value from cells treatedwith the ligand in the absence of inhibitor has been arbitrarily assigned as 1) [SP, SP600125; Cur, curcumin; LY, LY294002;+, 22-(R)-HC plus 9cRA; *pb0.05; **pb0.01;
and ***pb0.001].
545E.A. Huwait et al. / Cellular Signalling 23 (2011) 542–549of both phospho-AKT and its activity were inhibited by LY294002
(Fig. 4C–E).
3.4. LXR agonists induce activator protein-1 (AP-1) DNA binding
Because c-Jun, which belongs to the AP-1 family of transcription
factors, is a key downstream target for JNK [21], the action of theligands on AP-1 DNA binding was analyzed by EMSA using a probe
containing the consensus binding sequence. Either 22-(R)-HC plus
9cRA or TO901317 increased AP-1 binding using whole cell or nuclear
extracts (Fig. 5A). The positive action of the ligands was conﬁrmed by
monitoring the expression of the ABCA1 protein (data not shown).
Competition EMSA using extracts from ligand-treated cells showed
that the DNA-protein complexes were markedly competed out with
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Fig. 3. The 22-(R)-HC/9cRA-induced gene expression is attenuated by the JNK and PI3K
inhibitors in HMDM and by dominant negative forms of proteins of these pathways in
transfected cells. (A) HMDM were pre-treated for 1 h with 10 μM curcumin (Cur), 50 μM
SP600125(SP), 50 μMLY294002(LY)or theDMSOvehicle (−)and then incubated for24 h in
medium containing the ligand 22-(R)-HC plus 9cRA (2 μg/ml/10 μM) (+) or the vehicle (−).
The total RNA was subjected to RT-qPCR using primers for ApoE or 28S rRNA. The
ApoE:28SrRNA ratio from cells treated with vehicle alone has been arbitrarily assigned as 1,
with those from the other samples represented to this value (mean±SD from three
independent experiments; *pb0.05). (B) U937 cells were co-transfected with the ABCA1
promoter-luciferase DNA construct along with the pcDNA3 vector or expression plasmids
specifying for dominant negative (DN) forms of LXR-α, SEK1, c-Jun andAKT as indicated. The
cells were then differentiated for 18 h using 0.16 μM phorbol 12-myristate 13-acetate in the
presence of 2 μg/ml 22-(R)-HC plus 10 μM 9cRA or DMSO vehicle. In each case the relative
luciferase activity, normalized to protein concentration, from vehicle-treated cells has been
arbitrarily assigned as 1 (not shown) with those from cells incubated with the ligands
represented to this value (mean±SD from three independent experiments; *pb0.05).
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by containing the unrelated C/EBP or NF-κB binding site (Fig. 5B).
Curcumin has previously been shown to inhibit c-Jun/AP-1 binding
[22] and this was also found to be the case for the LXR agonist-induced
AP-1 activity (Fig. 5C).
The studies so far employed a consensus AP-1 binding site and the
ﬁndings were therefore extended to natural promoters. An AP-1-like
sequence has been identiﬁed in the promoter of the ApoE gene [23].
EMSA showed that protein binding to this site was also induced by the
treatment of the cells with 22-(R)-HC plus 9cRA or TO901317
(Fig. 6A). The proximal promoter region of the human ABCA1 gene
also contains binding sites for several transcription factors, including
AP-1 [24]. EMSA using an oligonucleotide containing one of these sites
(−131 to −111) again demonstrated increased binding when
extracts from ligand-treated cells were used (Fig. 6A). Competition
EMSA showed that the formation of DNA-protein complexes was
abolished by an oligonucleotide containing the AP-1 binding site but
not for NF-κB (Fig. 6B).Fig. 4. 22-(R)-HC plus 9cRA activate the JNK and PI3K pathways and this is attenuated by the cor
indicated concentrations of SP600125, 30 μMcurcumin (Cur) or 100 μMLY294002. The cellswere t
plus 10 μM9cRA (DMSOwasused as a vehicle control;−).Whole cell extractswere subjected toW
Tot/t, respectively) of JNK, SEK1, c-Jun or AKT (panels A and C) or in vitro kinase assay (panels B and
fusionprotein (FP) substrate ismonitoredbyWesternblot analysis (c-Jun for JNK in panel B andGS
and c-Jun in panel A) and three (SEK1 inpanel A alongwith panels C andD) experiments. (E) densi
p-GSK-3α/β:β-actin ratioswere determined. The ratios fromcells treatedwith the vehicle alone or
represented to this (mean±SD from three independent experiments) (*pb0.05 and **pb0.01).4. Discussion
LXR ligands attenuate atherosclerosis by controlling several
cellular events, including the stimulation of macrophage cholesterol
efﬂux through the expression of key genes implicated in this process,
such as ApoE and ABCA1. The action of nuclear receptor agonists in the
regulation of gene transcription is complex with control by intracel-
lular signaling pathways of the receptors themselves, co-factors
recruited by them or other transcription factors that are required for
the maximal expression of downstream genes [7]. Unfortunately, the
impact of intracellular signaling on the actions of LXR agonists in the
regulation of gene expression is poorly understood. Using a
combination of inhibitors, biochemical analysis and use of plasmids
specifying for dominant negative proteins, we show for the ﬁrst time
an important role for the JNK and PI3K pathways in the LXR agonists-
induced expression of these genes in macrophages.
Previous studies have suggested potential roles for protein kinase A
(PKA), protein kinase C (PKC) and casein kinase 2 (CK2) in the
regulation of LXR activity although none of these has been in human
macrophages in relation to genes associated with cholesterol efﬂux.
For example,Huang et al. [25] showed a synergistic activation of LXR-α
by 22-(R)-HC and agents triggering PKA and PKC signaling in CHOK1
cells. In contrast to this, PKA was found to suppress the expression in
hepatocytes of sterol regulatory element binding protein 1c, a key
downstream target of LXR actions, through the phosphorylation of
LXR-α [26]. The role of PKA therefore appears to be gene- and/or cell-
type-speciﬁc. LXR-α has also been found to be phosphorylated on
serine 198 (S198) under basal conditions and this was enhanced by
TO901317 and reduced by CK2 inhibitors or 9cRA [27]. The action of
this phosphorylationwas gene-speciﬁc as the expression of only some
LXR targets was increased in cells expressing the S198A phos-
phorylation-deﬁcient mutant compared to those for the wild-type
receptor [27].
The exactmechanism throughwhich LXR agonists activate JNK and
PI3K and ultimately how these modulate the actions of this nuclear
receptor remains to be determined. In relation to the activation of the
signaling pathways, studies on other nuclear receptors have shown
that these often represent the so called non-genomic effects [28]. This
involves a rapid, transient activation of intracellular signaling cascades
often mediated by a subpopulation of the receptor at the cytoplasmic
side of the membrane [28]. Although such cytoplasmic receptors exist
for a number of nuclear receptors, including the PPARs, to our
knowledge this has not yet been identiﬁed for the LXRs. In relation
to the potential mechanisms, agonists don't affect LXR DNA binding so
steps subsequent to these are likely to be affected, such as the
phosphorylation of the LXRs leading to promotion of co-activator
recruitment at target gene promoters and/or the release of co-
repressors and/or direct modulation of the activity of such co-factors
by phosphorylating them in a ligand-dependentmanner. For example,
the PKA-mediated phosphorylation of LXRα has been shown to reduce
the recruitment of the SRC-1 coactivator and enhance the recruitment
of the corepressor NCoR1 [26].
LXR agonists induced the binding of AP-1, a key factor regulated by
JNK, to its recognition sequences in several gene promoters.
Interestingly, LXR agonists have also been found to activate AP-1 in
keratinocytes and this has been linked to the regulation of expression
of key genes implicated in epidermal differentiation [29]. It is thusresponding inhibitors. THP-1 macrophages were pre-treated for 1 h with vehicle (−) or the
hen incubated for 24 h (panels AandB)or 1 h (panels C andD)with2 μg/ml22-(R)-HC (22R)
esternblot analysis using antisera that recognize phosphorylated and total levels (phos/p and
D). In the latter, the ability of immunoprecipitated proteins to phosphorylate its downstream
K-3α/β for AKT inpanelD). The data shownare representative of two (panel B alongwith JNK
tometric analysiswas carried out on the data shown in panels C andDand thep-AKT:t-AKTor
in the presence of the ligands have been arbitrarily assigned as 1, as indicated,with the others
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Fig. 5. LXR activators induce AP-1 DNA binding. THP-1 macrophages were incubated for
24 hwith 2 μg/ml 22-(R)-HC (22R) plus 10 μM9cRA, 10 μMTO901317 (T1317) or 2 μg/ml
22-(S)-HC (22S) (panels A and B). For panel C, the cells were pre-treated for 1 h with the
vehicle or the indicated concentration of curcumin (Cur) before the addition of the ligands.
Whole cell extracts (WCE) or nuclear extracts (NE) were prepared and used for EMSA
using a consensus AP-1 binding site probe. The competition assays in panel B employed a
200-fold molar excess of unlabelled speciﬁc AP-1 sequence (S) or for the unrelated C/EBP
orNF-κB binding sites (NS forWCE andNE, respectively). TheAP-1:DNA complex and free
probe are indicated by vertical lines labelled C and F, respectively (the free probe has
migrated off the gel for NE in panels A and B and in panel C). The data shown are
representative of two independent experiments.
Fig. 6. LXRactivators induceAP-1binding to its recognitionsequences in theApoEandABCA1
gene promoters. THP-1macrophageswere incubated for 24 hwith 2 μg/ml 22-(R)-HC (22R)
plus10 μM9cRAor10 μMTO901317 (T1317)as indicated.Whole cell extractswereprepared
and used for EMSA using radiolabelled probe containing an AP-1 binding site from the ApoE
gene promoter (ApoE) or a putative recognition sequence in the regulatory region of the
ABCA1gene (ABCA1). The competition assays inpanel B employed a200-foldmolar excess of
unlabelled speciﬁc AP-1 sequence (S) or for the unrelated NF-κB binding site (NS). Themajor
DNA:protein complexes are shown by a vertical line labelled C (the free probe has migrated
off the gel in panel B). The data shown are representative of two to three independent
experiments.
548 E.A. Huwait et al. / Cellular Signalling 23 (2011) 542–549possible that such activation of AP-1 might also play important roles
in the actions of LXRs in macrophages such as the maximal expression
of downstream genes such as ApoE and ABCA1, the promoter regions
ofwhich containAP-1binding sites [23,24], or regulating the expression
of key components involved in LXR-mediated gene transcription.In conclusion, we have identiﬁed a key role for JNK/c-Jun/AP-1 in the
LXR agonists-mediated induction of several key genes implicated in the
control of macrophage cholesterol homeostasis. These signaling compo-
nents are likely to play an important role in atherosclerosis, given that
LXR agonists act in an anti-atherogenic manner. Future studies should
seek to delineate how these agonists activate the identiﬁed signaling
pathways and modulate LXR actions on downstream genes.
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